Genzyme, a Sanofi company (SNY) Friday announced positive results from the TOWER trial for Treatment and Research in Multiple Sclerosis.
TOWER is a Phase III, multi-center double-blind parallel-group placebo-controlled study of the efficacy and safety of AUBAGIO in patients with relapsing MS followed by an open-label extension period.
The company, engaged in the the development and delivery of transformative therapies for patients affected by rare and debilitating diseases for over 30 years, stzted thzt in the study, once-daily, oral AUBAGIO 14 mg significantly reduced the annualized relapse rate and slowed progression of disability in patients with relapsing forms of multiple sclerosis (MS) compared to placebo.
The company further added that the proportion of patients treated with AUBAGIO who were relapse-free was significantly higher compared to placebo.
For comments and feedback contact: editorial@rttnews.com
Business News